KRN 330

Drug Profile

KRN 330

Alternative Names: KRN-330

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Kirin Pharma Company
  • Developer Kyowa Hakko Kirin
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Differentiation antigen inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Colorectal cancer

Most Recent Events

  • 18 Oct 2012 Discontinued - Phase-I for Colorectal cancer in USA (Parenteral)
  • 18 Oct 2012 Discontinued - Phase-I/II for Colorectal cancer (combination therapy) in USA (Parenteral)
  • 10 Oct 2012 Kyoa Hakko Kirin terminates a phase I/IIa trial in Colorectal cancer in US (NCT00838578)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top